RecruitingNCT06426628

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

Clinical Utility of Management of Patients With CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier


Sponsor

Veracyte, Inc.

Enrollment

2,400 participants

Start Date

Jul 18, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? * Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is cancer? Participants will be randomly assigned to either a group where the test result is provided to the physician (test arm) or to a group where the test result is not provided (control arm). Researchers will compare management of participants in the two groups.


Eligibility

Min Age: 29 YearsMax Age: 85 Years

Inclusion Criteria8

  • Able to tolerate nasal epithelial specimen collection
  • Signed written Informed Consent obtained
  • Subject clinical history available for review by sponsor and regulatory agencies
  • New nodule identified on imaging \< 90 days prior to nasal sample collection
  • CT report available for index nodule
  • years of age
  • Current or former smoker (\>100 cigarettes in a lifetime)
  • Pulmonary nodule ≤30 mm detected by CT

Exclusion Criteria6

  • Active cancer (other than non-melanoma skin cancer)
  • Prior primary lung cancer (prior non-lung cancer acceptable)
  • Prior participation in this study (i.e., subjects may not be enrolled more than once)
  • Current active treatment with an investigational device or drug
  • Patient enrolled or planned to be enrolled in another clinical trial that may influence management of the patient's nodule
  • Concurrent or planned use of tools or tests for assigning lung nodule risk of malignancy other than clinically validated risk calculators

Locations(23)

Trinity Health Of New England

Hartford, Connecticut, United States

The Stamford Health/The Stamford Hospital

Stamford, Connecticut, United States

Bay Pines VA HCS

Bay Pines, Florida, United States

North Florida/South Georgia Veterans Health System

Gainesville, Florida, United States

Bruce W. Carter Miami VA Medical Center

Miami, Florida, United States

Orlando VA Healthcare System

Orlando, Florida, United States

Northwestern University

Chicago, Illinois, United States

OSF Saint Francis Medical Center

Peoria, Illinois, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

Lexington VA Health Care System

Lexington, Kentucky, United States

Robley Rex VA Medical Center

Louisville, Kentucky, United States

Southeast Louisiana Veterans Health Care System

New Orleans, Louisiana, United States

University of Maryland Medical Center

Baltimore, Maryland, United States

Boston University Medical Center

Boston, Massachusetts, United States

Saint Lukes Hospital

Kansas City, Missouri, United States

Mercy Hospital

Springfield, Missouri, United States

University of Rochester Medical Center

Rochester, New York, United States

Good Samaritan Cancer Center

West Islip, New York, United States

PulmonIx, LLC

Greensboro, North Carolina, United States

University of Cincinnati

Cincinnati, Ohio, United States

Mercy Health St. Vincent Medical Center

Toledo, Ohio, United States

Ralph H. Johnson VA Health Care System

Charleston, South Carolina, United States

VA Caribbean Healthcare

San Juan, Puerto Rico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06426628


Related Trials